Richard Jones

Richard Jones

Amministratore Delegato presso AdrenoMed AG

51 anni
Health Technology
Consumer Services
Health Services

Profilo

Richard Jones currently works at AdrenoMed AG, as Chief Executive Officer from 2022.
Dr. Jones also formerly worked at Fusion Antibodies Plc, as Chief Executive Officer & Director from 2021 to 2022, Akinion Pharmaceuticals AB, as Chief Executive Officer, BrYet Ltd., as Chief Executive Officer & Director in 2020, Holostem Terapie Avanzate S R L, as Chief Executive Officer, Genzyme Corp., as Director-Oncology & Transplant Portfolio, GSK Plc, as Vice President-Global Commercial Leader, Novartis UK Ltd., as VP-Medicines Commercialization, and Akcea Therapeutics UK Ltd., as Senior Vice President & Head-Europe.
Dr. Jones received his undergraduate degree and doctorate degree from the University of Surrey.

Posizioni attive di Richard Jones

SocietàPosizioneInizio
Amministratore Delegato 15/03/2022
Tutte le posizioni attive di Richard Jones

Precedenti posizioni note di Richard Jones

SocietàPosizioneFine
FUSION ANTIBODIES PLC Amministratore Delegato 11/03/2022
BrYet Ltd. Amministratore Delegato 01/07/2020
Corporate Officer/Principal -
GSK PLC Corporate Officer/Principal -
Corporate Officer/Principal -
Vedi nel dettaglio l'esperienza di Richard Jones

Formazione di Richard Jones

University of Surrey Doctorate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Richard Jones

Relazioni

8

Relazioni di 1° grado

10

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa2
GSK PLC

Health Technology

FUSION ANTIBODIES PLC

Health Services

Aziende private7

Health Technology

Health Technology

Health Technology

Akcea Therapeutics UK Ltd.

BrYet Ltd.

Holostem Terapie Avanzate S R L

Health Technology

Vedi le connessioni aziendali
-40% Offerta a tempo limitato: i nostri abbonamenti ti guidano verso i migliori investimenti di domani.
APPROFITTANE ORA